Table 3.

EGFR and Src kinases inhibitory activity of 1,3,4-oxadiazole/chalcone hybrids.

Compound	EGFR (IC50 μM)	Src (IC50 μM)	Compound	EGFR (IC50 μM)	Src (IC50 μM)
8a	1.23 ± 0.25	4.5 ± 1.2	8n	2.35 ± 0.95	6.24 ± 0.86
8b	35.15 ± 1.36	44.1 ± 3.5	8o	71.15 ± 3.25	51.24 ± 5.6
8c	64.35 ± 3.56	57.3 ± 2.4	8p	13.26 ± 0.65	13.67 ± 0.89
8d	11.22 ± 1.25	13.41 ± 1.6	8q	11.38 ± 1.54	29.48 ± 1.23
8e	59.35 ± 5.63	74.4 ± 3.6	8r	63.25 ± 2.36	76.2 ± 3.65
8f	64.68 ± 3.65	50.32 ± 3.5	8s	12.35 ± 0.8	15.34 ± 1.25
8g	12.67 ± 1.25	22.14 ± 2.15	8t	22.34 ± 2.35	40.21 ± 1.34
8h	30.25 ± 2.35	41.36 ± 4.5	8u	55.45 ± 4.35	53.09 ± 5.6
8i	29.34 ± 3.65	43.67 ± 3.5	8v	0.24 ± 0.035	0.96 ± 0.2
8j	11.47 ± 1.24	25.34 ± 1.56	8w	48.34 ± 2.36	60.34 ± 2.5
8k	18.34 ± 2.35	33.64 ± 2.35	8x	20.5 ± 1.35	35.12 ± 3.26
8l	12.34 ± 1.35	24.98 ± 3.46	Dasatinib	0.8 ± 0.23	< 0.001
8m	10.24 ± 0.36	12.5 ± 0.3	Gefitinib	0.023 ± 0.004	1.25 ± 0.15